In this issue:
- Lipid lowering effects of obicetrapib with high-intensity statin
- HDL-C levels and adverse CV outcomes
- Coronary plaques, LDL-C levels and CVD events
- LDL-C and CV and renal outcomes in moderate CKD
- Lipoprotein(a), DAPT and outcomes after drug-eluting stent
- Bempedoic acid for patients not receiving statins
- Attainment of LDL-C goals with combination therapy
- Lipoprotein(a) in ASCVD and aortic stenosis
- Lipoprotein(a) levels in a global population
- Pharmacotherapy in type 2 diabetes and ASCVD
- Attainment of lipid targets following CABG surgery
- Association of lipoprotein(a) with atherosclerotic plaque progression
- Early statin therapy in ACS patients
- Moderate-intensity statin + ezetimibe vs high-intensity statin in ASCVD
- Protective effects of statins on COVID-19
Download the Lipids Year in Review 2022, with commentary by A/Prof John Amerena (pdf)